CN113557010A - 用于递送治疗剂的腺相关病毒载体 - Google Patents

用于递送治疗剂的腺相关病毒载体 Download PDF

Info

Publication number
CN113557010A
CN113557010A CN202080017179.5A CN202080017179A CN113557010A CN 113557010 A CN113557010 A CN 113557010A CN 202080017179 A CN202080017179 A CN 202080017179A CN 113557010 A CN113557010 A CN 113557010A
Authority
CN
China
Prior art keywords
sequence
type
seq
target
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080017179.5A
Other languages
English (en)
Chinese (zh)
Inventor
安·J·利戈基
卡梅罗·罗曼诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN113557010A publication Critical patent/CN113557010A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Botany (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080017179.5A 2019-02-28 2020-02-27 用于递送治疗剂的腺相关病毒载体 Pending CN113557010A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962812017P 2019-02-28 2019-02-28
US62/812,017 2019-02-28
US201962831838P 2019-04-10 2019-04-10
US62/831,838 2019-04-10
US201962878865P 2019-07-26 2019-07-26
US62/878,865 2019-07-26
PCT/US2020/020134 WO2020176747A1 (en) 2019-02-28 2020-02-27 Adeno-associated virus vectors for the delivery of therapeutics

Publications (1)

Publication Number Publication Date
CN113557010A true CN113557010A (zh) 2021-10-26

Family

ID=70155318

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080017179.5A Pending CN113557010A (zh) 2019-02-28 2020-02-27 用于递送治疗剂的腺相关病毒载体

Country Status (8)

Country Link
US (1) US20220047618A1 (enExample)
EP (1) EP3930694A1 (enExample)
JP (2) JP2022522756A (enExample)
CN (1) CN113557010A (enExample)
AU (2) AU2020229871B2 (enExample)
CA (1) CA3131919A1 (enExample)
IL (1) IL285639A (enExample)
WO (1) WO2020176747A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022216614B2 (en) 2021-02-05 2026-03-05 Christiana Care Gene Editing Institute, Inc. Methods of and compositions for reducing gene expression and/or activity
CN115505593B (zh) * 2021-06-23 2025-10-10 武汉纽福斯生物科技有限公司 寡核苷酸、病毒载体及其应用和RNAi药物制剂
US20250319202A1 (en) * 2021-11-09 2025-10-16 Prime Medicine, Inc. Genome editing compositions and methods for treatment of fuchs endothelial corneal dystrophy
WO2023111351A1 (en) * 2021-12-17 2023-06-22 Christian Kupatt Aav vectors for gene therapy in endothelial cells

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899658A (zh) * 2013-12-12 2016-08-24 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
CN106061510A (zh) * 2013-12-12 2016-10-26 布罗德研究所有限公司 用于基因组编辑的crispr‑cas系统和组合物的递送、用途和治疗应用
WO2017185054A1 (en) * 2016-04-22 2017-10-26 Intellia Therapeutics, Inc. Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four
CN107849547A (zh) * 2015-05-16 2018-03-27 建新公司 深内含子突变的基因编辑
CN108291225A (zh) * 2015-10-05 2018-07-17 ProQR治疗上市公司Ⅱ 单链反义寡核苷酸在预防或治疗涉及三核苷酸重复扩增的遗传疾病中的用途
WO2018161035A1 (en) * 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
WO2018165541A1 (en) * 2017-03-10 2018-09-13 The Board Of Regents Of The University Of Texas System Treatment of fuchs' endothelial corneal dystrophy
WO2019025984A1 (en) * 2017-07-31 2019-02-07 Reflection Biotechnologies Limited CELLULAR MODELS AND THERAPIES FOR OCULAR DISEASES

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN103502458B (zh) 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
IL251178B (en) 2014-09-16 2022-07-01 Genzyme Corp Adeno-associated viral vector for the treatment of glaucoma myocilin (myoc)
WO2017178590A1 (en) * 2016-04-14 2017-10-19 Université de Lausanne Treatment and/or prevention of dna-triplet repeat diseases or disorders
EP3342868B1 (en) * 2016-12-30 2019-12-25 Systasy Bioscience GmbH Constructs and screening methods

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899658A (zh) * 2013-12-12 2016-08-24 布罗德研究所有限公司 针对hbv和病毒性疾病以及障碍的crispr-cas系统和组合物的递送、用途和治疗应用
CN106061510A (zh) * 2013-12-12 2016-10-26 布罗德研究所有限公司 用于基因组编辑的crispr‑cas系统和组合物的递送、用途和治疗应用
CN107849547A (zh) * 2015-05-16 2018-03-27 建新公司 深内含子突变的基因编辑
CN108291225A (zh) * 2015-10-05 2018-07-17 ProQR治疗上市公司Ⅱ 单链反义寡核苷酸在预防或治疗涉及三核苷酸重复扩增的遗传疾病中的用途
WO2017185054A1 (en) * 2016-04-22 2017-10-26 Intellia Therapeutics, Inc. Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four
WO2018161035A1 (en) * 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
WO2018165541A1 (en) * 2017-03-10 2018-09-13 The Board Of Regents Of The University Of Texas System Treatment of fuchs' endothelial corneal dystrophy
WO2019025984A1 (en) * 2017-07-31 2019-02-07 Reflection Biotechnologies Limited CELLULAR MODELS AND THERAPIES FOR OCULAR DISEASES

Also Published As

Publication number Publication date
WO2020176747A1 (en) 2020-09-03
EP3930694A1 (en) 2022-01-05
JP2025061656A (ja) 2025-04-11
IL285639A (en) 2021-09-30
US20220047618A1 (en) 2022-02-17
JP2022522756A (ja) 2022-04-20
AU2020229871B2 (en) 2023-05-18
AU2020229871A1 (en) 2021-10-21
CA3131919A1 (en) 2020-09-03
AU2023216849A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
AU2020260765B2 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
AU2018260998B2 (en) Modulatory polynucleotides
AU2018261790B2 (en) Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
AU2024278250A1 (en) Compositions and methods of treating Huntington's Disease
EP3662066A1 (en) Cellular models of and therapies for ocular diseases
JP2025061656A (ja) 治療薬の送達のためのアデノ随伴ウイルスベクター
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
KR20250011939A (ko) Abca4 트랜스-스플라이싱 분자
WO2023212273A1 (en) Treatments for age-related macular degeneration
CN119630433A (zh) 基因疗法组合物及其使用方法
JP7701359B2 (ja) 変形性関節症の治療方法
WO2024069144A1 (en) Rna editing vector
CN111944814B (zh) 寡核苷酸、病毒载体及其应用和RNAi药物制剂
CN116194474A (zh) 遗传性扩张型心肌病的治疗
US20250257355A1 (en) Antisense oligonucleotides for treatment of USHER 2A. Exons 30-31
WO2025231487A1 (en) Photoreceptor specific promotors for use in gene therapies for treatment of retinal degeneration
WO2025036833A1 (en) Antisense oligonucleotides for treatment of usher 2a. exon 53
EP4619522A1 (en) Antisense oligonucleotides for treatment of usher 2a. exons 39-40
WO2025016362A1 (zh) 基于脑内磷稳态促进剂的疗法
HK40093831A (en) Rho-r135w-adrp gene editing drug based on gene editing
CN118256496A (zh) 用于治疗视网膜色素变性的组合物和方法
CN116194121A (zh) 用于治疗扩张型心肌病的cilp-1抑制剂
CN106729752A (zh) A型尼曼‑皮克病的基因治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination